La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions.

Identifieur interne : 000D37 ( Main/Exploration ); précédent : 000D36; suivant : 000D38

Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions.

Auteurs : Danielle Murray [Canada] ; A Jon Stoessl

Source :

RBID : pubmed:23880289

English descriptors

Abstract

The power of a placebo to effect clinically meaningful neurobiological change comparable to pharmacological therapies has been demonstrated, although the mechanisms are not fully understood. Predicting placebo responsiveness has only recently received more attention, but psychological disposition, contextual and biological factors are now known to dramatically affect a person's susceptibility to the placebo effect. The placebo effect depends upon expectancies that can be modified in a number of ways, including conditioning through explicit or implicit learned associations. Based on the dopaminergic response to anticipation of benefit in Parkinson's disease, it was suggested that the placebo effect can be seen as analogous to the expectation of reward. Dopaminergic pathways have since been implicated in the placebo response in pain and depression. Additionally, endogenous opioid release is known to mediate many forms of placebo analgesia. We provide an overview of the mechanisms and the therapeutic implications of the placebo effect in neurological and psychiatric conditions. We include evidence for detrimental effects arising from seemingly inert interventions, termed the 'nocebo effect.' Neuroimaging has critically advanced the study of the placebo effect and provides some of the strongest evidence for the mechanisms of this phenomenon prevalent across an array of human health-related circumstances. This review specifically focuses on mechanisms of the placebo effect in the three conditions that have most significantly demonstrated this effect and for which a plausible physiological basis can be identified: pain, PD and depression. Other neurological and psychiatric diseases reviewed include multiple sclerosis, Huntington's disease, Alzheimer's disease, schizophrenia and epilepsy.

DOI: 10.1016/j.pharmthera.2013.07.009
PubMed: 23880289


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions.</title>
<author>
<name sortKey="Murray, Danielle" sort="Murray, Danielle" uniqKey="Murray D" first="Danielle" last="Murray">Danielle Murray</name>
<affiliation wicri:level="1">
<nlm:affiliation>Pacific Parkinson's Research Centre and Department of Medicine, Division of Neurology, University of British Columbia & Vancouver Coastal Health, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Pacific Parkinson's Research Centre and Department of Medicine, Division of Neurology, University of British Columbia & Vancouver Coastal Health</wicri:regionArea>
<wicri:noRegion>University of British Columbia & Vancouver Coastal Health</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A Jon" last="Stoessl">A Jon Stoessl</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23880289</idno>
<idno type="pmid">23880289</idno>
<idno type="doi">10.1016/j.pharmthera.2013.07.009</idno>
<idno type="wicri:Area/PubMed/Corpus">000835</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000835</idno>
<idno type="wicri:Area/PubMed/Curation">000835</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000835</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000835</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000835</idno>
<idno type="wicri:Area/Ncbi/Merge">001515</idno>
<idno type="wicri:Area/Ncbi/Curation">001515</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001515</idno>
<idno type="wicri:Area/Main/Merge">000D48</idno>
<idno type="wicri:Area/Main/Curation">000D37</idno>
<idno type="wicri:Area/Main/Exploration">000D37</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions.</title>
<author>
<name sortKey="Murray, Danielle" sort="Murray, Danielle" uniqKey="Murray D" first="Danielle" last="Murray">Danielle Murray</name>
<affiliation wicri:level="1">
<nlm:affiliation>Pacific Parkinson's Research Centre and Department of Medicine, Division of Neurology, University of British Columbia & Vancouver Coastal Health, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Pacific Parkinson's Research Centre and Department of Medicine, Division of Neurology, University of British Columbia & Vancouver Coastal Health</wicri:regionArea>
<wicri:noRegion>University of British Columbia & Vancouver Coastal Health</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A Jon" last="Stoessl">A Jon Stoessl</name>
</author>
</analytic>
<series>
<title level="j">Pharmacology & therapeutics</title>
<idno type="eISSN">1879-016X</idno>
<imprint>
<date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Humans</term>
<term>Mental Disorders (drug therapy)</term>
<term>Mental Disorders (pathology)</term>
<term>Nervous System Diseases (drug therapy)</term>
<term>Nervous System Diseases (pathology)</term>
<term>Placebo Effect</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Mental Disorders</term>
<term>Nervous System Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Mental Disorders</term>
<term>Nervous System Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Humans</term>
<term>Placebo Effect</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The power of a placebo to effect clinically meaningful neurobiological change comparable to pharmacological therapies has been demonstrated, although the mechanisms are not fully understood. Predicting placebo responsiveness has only recently received more attention, but psychological disposition, contextual and biological factors are now known to dramatically affect a person's susceptibility to the placebo effect. The placebo effect depends upon expectancies that can be modified in a number of ways, including conditioning through explicit or implicit learned associations. Based on the dopaminergic response to anticipation of benefit in Parkinson's disease, it was suggested that the placebo effect can be seen as analogous to the expectation of reward. Dopaminergic pathways have since been implicated in the placebo response in pain and depression. Additionally, endogenous opioid release is known to mediate many forms of placebo analgesia. We provide an overview of the mechanisms and the therapeutic implications of the placebo effect in neurological and psychiatric conditions. We include evidence for detrimental effects arising from seemingly inert interventions, termed the 'nocebo effect.' Neuroimaging has critically advanced the study of the placebo effect and provides some of the strongest evidence for the mechanisms of this phenomenon prevalent across an array of human health-related circumstances. This review specifically focuses on mechanisms of the placebo effect in the three conditions that have most significantly demonstrated this effect and for which a plausible physiological basis can be identified: pain, PD and depression. Other neurological and psychiatric diseases reviewed include multiple sclerosis, Huntington's disease, Alzheimer's disease, schizophrenia and epilepsy.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Canada</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A Jon" last="Stoessl">A Jon Stoessl</name>
</noCountry>
<country name="Canada">
<noRegion>
<name sortKey="Murray, Danielle" sort="Murray, Danielle" uniqKey="Murray D" first="Danielle" last="Murray">Danielle Murray</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D37 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D37 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:23880289
   |texte=   Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23880289" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022